[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1976

Systemic Chemotherapy For PsoriasisA National Survey

Author Affiliations

From the Department of Dermatology (Drs Bergstresser and Weinstein and Ms Schreiber), University of Miami School of Medicine and the Miami Veterans Administration Hospital (Dr Bergstresser), Miami, Fla.

Arch Dermatol. 1976;112(7):977-981. doi:10.1001/archderm.1976.01630310039008
Abstract

• A questionnaire that was mailed to 510 randomly selected dermatologists in the United States surveyed their use of three systemic chemotherapeutic agents for the treatment of psoriasis during the two-year period of 1973 to 1974. Methotrexate was used by 52% of the surveyed dermatologists, while hydroxyurea and azaribine were used by 10% and 2%, respectively. Seventy-five percent of the dermatologists who used methotrexate treated ten or fewer psoriatic patients with this drug. Multiple dose therapy with methotrexate divided over a period of 36 hours each week was the preferred schedule of 66% of the dermatologists. Liver biopsy specimens and creatinine clearance tests were obtained for only 17% and 35% of patients, respectively, prior to initiating methotrexate therapy. The estimated number of dermatologisttreated psoriatics nationwide receiving methotrexate is 25,000.

(Arch Dermatol 112:977-981, 1976)

×